British journal of cancer · 1998

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH

Аннотация

Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Anderson H., Scarffe J. H., Ranson M., Young R., Wieringa G. S., Morgenstern G. R., Fitzsimmons L., Ryder D. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 1995 Feb;71(2):326–330. doi: 10.1038/bjc.1995.65.

Case D. C., Jr, Lee D. J., 3rd, Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977 Dec;63(6):897–903. doi: 10.1016/0002-9343(77)90543-5.

Comenzo R. L., Vosburgh E., Simms R. W., Bergethon P., Sarnacki D., Finn K., Dubrey S., Faller D. V., Wright D. G., Falk R. H. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996 Oct 1;88(7):2801–2806.

Fielder K., Durie B. G. Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy. Am J Med. 1986 Mar;80(3):413–418. doi: 10.1016/0002-9343(86)90715-1.

Gertz M. A., Kyle R. A., Greipp P. R. Response rates and survival in primary systemic amyloidosis. Blood. 1991 Jan 15;77(2):257–262.

Gertz M. A., Kyle R. A. Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc. 1989 Dec;64(12):1505–1519. doi: 10.1016/s0025-6196(12)65706-1.

Hawkins P. N., Myers M. J., Lavender J. P., Pepys M. B. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet. 1988 Jun 25;1(8600):1413–1418. doi: 10.1016/s0140-6736(88)92235-0.

Kyle R. A., Gertz M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995 Jan;32(1):45–59.

Kyle R. A., Greipp P. R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983 Oct;58(10):665–683.

Kyle R. A., Greipp P. R., Garton J. P., Gertz M. A. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708–716. doi: 10.1016/0002-9343(85)90521-2.

Lévy Y., Belghiti-Deprez D., Sobel A. Traitement de l'amylose AL sans myélome. Ann Med Interne (Paris) 1988;139(3):190–193.

Merlini G., Ascari E., Amboldi N., Bellotti V., Arbustini E., Perfetti V., Ferrari M., Zorzoli I., Marinone M. G., Garini P. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2959–2963. doi: 10.1073/pnas.92.7.2959.

Skinner M., Anderson J., Simms R., Falk R., Wang M., Libbey C., Jones L. A., Cohen A. S. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996 Mar;100(3):290–298. doi: 10.1016/s0002-9343(97)89487-9.

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.

Ошибки и ограничения

Аннотация

Selected References